CMT drug receives Fast Track Designation

Published Date
05/02/2019
Author
Beatriz Bustillo Ramirez
Category
Research
Orange box stating: Breaking news research

French pharmaceutical company Pharnext has announced that PXT3003 has been granted Fast Track Designation by the US Food and Drug Administration (FDA). PXT3003 is a combination of three already-approved drugs that could potentially treat Charcot Marie Tooth disease type 1A (CMT 1A). Fast Track Designation gives Pharnext certain benefits that will help with the development of PXT3003.

For further information, please read Pharnext’s press release.

If you have any questions about this news story or any other CMT research, please contact the MDUK Research Line on 020 7803 4813 or email research@musculardystrophyuk.org.

Keep in touch